ICIvan Chebib

Ivan Chebib

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ivan Chebib has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Inter‐rater reliability of frozen donor liver macrovesicular steatosis assessment applying the Banff consensus method: a real‐world, multi‐specialty validation study

    by Derek M Loneman, Jarukit Tantipisit, Nicholas J Caldwell, Ting Zhao, Maxwell Roth, Miranda Machacek, Christos Tsokos, Kyle M Devins, Haihui Liao, M Lisa Zhang, et al.

    Introduction: Reliability of intraoperative assessment of donor liver allografts for steatosis, an important risk factor for future graft dysfunction, is limited by poor inter‐observer agreement. To address this issue, consensus guidelines by the Banff working group in 2022 proposed a standardized steatosis algorithm to improve agreement; however, the practical impact of the proposal has not been well‐validated across subspecialty practices and experience levels. Methods: This single‐institution inter‐observer agreement study entailed two rounds of evaluation of 27 frozen donor liver biopsies by 15 pathologists with a range of subspecialty expertise and experience levels. Raters estimated the amount of macrovesicular steatosis (MVS) by individual methods and, subsequently, using the proposed Banff algorithm. Results: Moderate agreement was observed among pooled raters, irrespective of method used (ICC 0.55 vs. 0.47 for individual and Banff methods, respectively) for precise estimation of MVS. Importantly, though, when precise estimates were reduced to clinically relevant grades, the Banff method improved agreement from ‘fair’ to ‘substantial’ compared with individual methods, with the most marked improvement among gastrointestinal subspecialists and pathologists with > 10 years of experience. The Banff method also resulted in overall lower grade estimates, with no ‘grade 3’ estimates provided, including from biopsies with abundant and azonal MVS, which are notoriously challenging. Conclusion: The findings support utilization of the Banff method as a means of improving inter‐rater agreement among diverse pathologists, resulting in more reliable estimation of MVS at clinically significant thresholds.

  • Clinicopathologic evaluation of dedifferentiated liposarcoma lacking MDM2 amplification

    by Charlotte I Wang, Soma Jobbagy, Anne B Giersch, Jonathan B Greer, Kevin X Liu, Gregory M Cote, Yin P Hung, G Petur Nielsen, Ivan Chebib

    Introduction: Dedifferentiated liposarcoma (DDLPS) is a typically non‐lipogenic malignant neoplasm that arises from progression of an underlying atypical lipomatous tumour/well‐differentiated liposarcoma (ALT/WDLPS) and is classically defined by amplification of chromosome 12q15, including MDM2 and frequently cyclin‐dependent kinase 4 ( CDK4 ). Detection of MDM2 amplification by fluorescence in situ hybridization (FISH) and/or MDM2 protein expression immunohistochemistry (IHC) has, therefore, become central to the diagnosis of DDLPS, particularly in small biopsies from the retroperitoneum. Rare exceptions to this paradigm have been described, but the clinicopathologic and molecular spectrum of MDM2 non‐amplified DDLPS remains poorly characterized. We report a series of MDM2 non‐amplified DDLPS to better define their diagnostic features, genomic alterations and clinical behaviour. Methods: Pathology archives from 2010 to 2025 were queried for cases diagnosed as DDLPS. Inclusion criteria required a high‐grade sarcoma arising in a histologically confirmed ALT/WDLPS background, absence of MDM2 overexpression by IHC and lack of MDM2 amplification by FISH and/or single nucleotide polymorphism array. Clinicopathologic features, immunophenotype, treatment and outcomes were reviewed. Results: Among 253 cases of DDLPS identified during the study period, four (1.6%) fulfilled criteria for MDM2 ‐negative DDLPS. All tumours arose in the retroperitoneum or intra‐abdominal soft tissues and demonstrated high‐grade sarcoma morphology with an associated WDLPS component on resection. Despite the absence of MDM2 amplification, all cases showed strong CDK4 expression by IHC. Molecular analysis revealed recurrent alterations involving cell‐cycle regulation, including CDK4 copy number gain in all cases and loss of CDKN2A in three. Two cases harboured TP53 alterations. Clinically, outcomes were heterogeneous, ranging from aggressive disease with rapid recurrence and death within months to prolonged disease‐free survival exceeding 5 years. Conclusion: MDM2 non‐amplified DDLPS represents a rare subset of DDLPS that appear to be driven by alternative mechanisms of cell‐cycle dysregulation, most commonly involving CDK4 gain and CDKN2A loss, with occasional TP53 alterations. Awareness of this variant is critical to avoid misclassification as other high‐grade sarcomas, particularly on limited biopsies, and underscores the importance of integrating morphology, IHC and broad genomic profiling in diagnostically challenging retroperitoneal sarcomas.


  • Histologic Distinction Between Clear Cell Sarcoma and Melanoma Using Supervised and Deep Learning

    by Jakob M. T. Moran, Ivan Chebib, Mark Sabbagh, Michael G. Drage, Mai P. Hoang, Jason L. Hornick, G. Petur Nielsen, Yin P. Hung

    Clear cell sarcoma overlaps histologically and immunophenotypically with melanoma. Molecular testing for EWSR1 rearrangement aids in their distinction but may not be readily available. We aim to construct machine learning‐based classifiers using supervised and deep learning. We digitized hematoxylin‐and‐eosin‐stained slides from clear cell sarcomas and melanomas with confirmatory testing, constructed nuclear morphometric‐based and deep learning‐based classifiers (using CLAM/ResNet‐50, CTransPath, and UNI models), and evaluated their performance using an independent external validation set. Morphometric analysis of 1,954,194 nuclei (1,308,124 from clear cell sarcomas, 646,070 from melanomas; 8700–70,726 [median 32,472] nuclei per slide) yielded two optimal classifiers using single‐node decision tree models; both pertained to nuclear perimeter and included interquartile/interdecile range normalized to median. Factors associated with inaccurate predictions included < 10,000 nuclei/sample and altered morphology in clear cell sarcoma due to therapy. In the external validation set, comparable to the prediction accuracies by four pathologists (median 80%; range 60%–100%), the two nuclear morphometric‐based classifiers achieved accuracies of 80%–90%, and the optimal deep learning‐based classifier CLAM/CTransPath showed an accuracy of 90%. In conclusion, we have derived interpretable nuclear morphometric‐ and deep learning‐based classifiers to distinguish clear cell sarcoma from melanoma. Quantitative morphometric analysis with machine learning holds the potential as a diagnostic adjunct.

  • “Benign” Metastasizing Fibrous Histiocytoma Harboring PRKCD Gene Fusions With Malignant Clinical Course

    by Charlotte I. Wang, Anne B. Giersch, Santiago Lozano Calderon, Edwin Choy, Fantine N. Giap, Yin P. Hung, G. Petur Nielsen, Ivan Chebib

    Dermatofibroma/fibrous histiocytoma is a common tumor of the dermis, composed of myofibroblasts, dendrocytes, and macrophages with characteristic entrapment of dermal collagen fibers at the periphery of the tumor. Various subtypes of dermatofibroma, including cellular, aneurysmal, and atypical dermatofibroma, are associated with an increased risk of recurrence, especially with incomplete excision. Two cases of benign fibrous histiocytoma with recurrence and metastasis are described. Patient 1 had a cellular fibrous histiocytoma with KIRREL1 :: PRKCD fusion presenting as a superficial and deep soft tissue mass involving the scapula and lateral clavicle. Patient 1 subsequently developed metastasis to the chest wall and thigh. Patient 2 had a recurrent aneurysmal fibrous histiocytoma with LAMTOR1 :: PRKCD fusion presenting as a large shoulder mass with invasion of the clavicle and lymph node metastasis. Patient 2 developed rapid local recurrence and PET‐avid pulmonary nodules, radiologically consistent with metastasis. Fibrous histiocytoma is typically a morphologically benign neoplasm that only rarely exhibits clinically aggressive behavior with multiple recurrences and metastases. Although uncommon, recognition of this entity is important so that pathologists and sarcoma oncologists can ensure accurate diagnosis, multidisciplinary management, and appropriate clinical surveillance. In addition, complex chromosomal abnormalities may serve as useful indicators of fibrous histiocytoma with the risk of aggressive clinical behavior.


  • Tumor necrosis drives prognosis in osteosarcoma: No difference in chemotherapy response and survival between chondroblastic and osteoblastic osteosarcoma

    by Neel Patel, Joseph O. Werenski, Marcos R. Gonzalez, Marilee J. Clunk, Meagan R. McCadden, Alexis Richard, Ivan Chebib, Yin P. Hung, G. Petur Nielsen, Santiago A. Lozano-Calderon


  • Emerging fusion-associated mesenchymal tumours: a tabular guide and appraisal of five ‘novel’ entities

    by Jinesa Moodley, Ivan Chebib

    Aims: The field of molecular pathology has undergone significant advancements in the clinical impact of sarcoma diagnosis, resulting in challenges to nosology of bone and soft tissue tumours. The surge in molecular data has led to the identification of novel fusions and description of new ‘entities’. To illustrate this, we have selected five emerging entities with novel fusions: clear cell stromal tumour of the lung with YAP1::TFE3 fusion, GAB1::ABL1 fusion spindle cell neoplasm, NUTM1 -rearranged sarcomas, NR1D1 -rearranged sarcomas and calcified chondroid mesenchymal neoplasms. Methods: Literature for the relevant case reports and case series of these five entities were reviewed and clinicopathological data was collected. Additionally, this review includes a table format of recently described fusion-associated mesenchymal neoplasms. Results: The morphological and immunohistochemical features, along with diagnostic challenges, are discussed for each entity. Conclusions: Here, we have provided a review of selected emerging mesenchymal neoplasms, which of these neoplasms will meet the threshold to be ‘new entities’ remains to be determined.


  • Utility of an anchored multiplex polymerase chain reaction‐based fusion assay for diagnosis of soft tissue tumors in cytology

    by T. Leif Helland, Adam S. Fisch, Ivan Chebib

    Background: Fine‐needle aspiration specimens from soft tissue tumors are complicated by lack of tissue architecture and limited material for ancillary testing. There are little data on the feasibility of next‐generation sequencing techniques for fusion detection on soft tissue cytology specimens. This study explored the role of an anchored multiplex polymerase chain reaction (PCR)‐based gene fusion assay in aiding the diagnosis of mesenchymal neoplasms on cytology samples.Methods: The laboratory information system was queried for cytology specimens that had undergone testing by anchored multiplex PCR. After exclusion of epithelial and hematolymphoid neoplasms, clinical and pathologic information was collected on the remaining cases.Results: There were 1609 cytology specimens tested with anchored multiplex PCR. Of these, 48 (3%) were cytology specimens from mesenchymal tumors. Anchored multiplex PCR was positive for a reportable fusion transcript in 14 of 48 cases (29%); there was no fusion detected in 32 cases (67%), and there was insufficient tissue for analysis in two cases (4%). The detectable fusion partners included ALK (n = 4), STAT6 (n = 4), EWSR1 (n = 3), and one each of SS18, YAP1, and PHF1. Of the cases in which a fusion partner was detected, eight of 14 were disease‐defining on cytology preparation, and six of 14 provided molecular confirmation of a metastatic focus of a previously diagnosed tumor.Conclusions: The anchored, multiplex PCR‐based gene fusion assay is a powerful orthogonal tool in helping diagnose mesenchymal neoplasms on cytology specimens. The material obtained for cytologic analysis yields sufficient quality/quantity of tissue in the majority of cases tested.


  • Interobserver agreement and diagnostic challenges of Congo red staining for amyloid detection on fat pad aspiration biopsies

    by Levent Trabzonlu, T. Leif Helland, Melanie C. Kwan, Nathalie Kumiega, M. Lisa Zhang, Ivan Chebib, Vanda F. Torous


  • Utility of LEF1 to differentiate desmoid fibromatosis from its histologic mimics

    by Soma Jobbagy, Santiago Lozano-Calderon, John T. Mullen, G. Petur Nielsen, Yin P. Hung, Ivan Chebib

    Diagnosis of desmoid-type fibromatosis (DF) may be challenging on biopsy due to morphologic overlap with reactive fibrosis (scar) and other uniform spindle cell neoplasms. Evaluation of nuclear β-catenin, a surrogate of Wnt pathway activation, is often difficult in DF due to weak nuclear expression and high background membranous/cytoplasmic staining. Lymphoid enhancer-factor 1 (LEF1) is a recently characterized effector partner of β-catenin which activates the transcription of target genes. We investigated the performance of LEF1 and β-catenin immunohistochemistry in a retrospective series of 156 soft tissue tumors, including 35 DF, 3 superficial fibromatosis, and 121 histologic mimics (19 soft tissue perineurioma, 8 colorectal perineurioma, 4 intraneural perineurioma, 26 scars, 23 nodular fasciitis, 6 low-grade fibromyxoid sarcomas, 6 angioleiomyomas, 5 neurofibromas, 5 dermatofibrosarcoma protuberans, 3 low-grade myofibroblastic sarcomas, 3 synovial sarcomas, 3 inflammatory myofibroblastic tumors, 2 schwannomas, and 1 each of Gardner-associated fibroma, radiation-associated spindle cell sarcoma, sclerotic fibroma, dermatofibroma, and glomus tumor). LEF1 expression was not only seen in 33/35 (94%) of DF but also observed in 19/23 (82%) nodular fasciitis, 7/19 (37%) soft tissue perineurioma, 2/3 (66%) synovial sarcoma, and 6/26 (23%) scar, as well as in 1 radiation-associated spindle cell sarcoma. The sensitivity and specificity of LEF1 IHC for diagnosis of DF were 94% and 70%, respectively. By comparison, β-catenin offered similar sensitivity, 94%, but 88% specificity. Positivity for LEF1 and β-catenin in combination showed sensitivity of 89%, lower than the sensitivity of β-catenin alone (94%); however, the combination of both LEF1 and β-catenin improved specificity (96%) compared to the specificity of β-catenin alone (88%). Although LEF1 has imperfect specificity in isolation, this stain has diagnostic utility when used in combination with β-catenin.